Celgene's Revlimid wins additional FDA lymphoma approval

[riky]

Celgene's Revlimid wins additional FDA lymphoma approval

(Reuters) - Celgene Corp said on Wednesday that its flagship blood cancer drug, Revlimid, was approved by U.S. health regulators to treat mantle cell lymphoma, adding another revenue source for the $4 billion-a-year medicine. The U.S. Food and Drug Administration approved Revlimid to treat mantle cell lymphoma (MCL) - a type of non-Hodgkin's lymphoma - that has relapsed or progressed following two prior treatment regimens, one of which must include Takeda Pharmaceutical Co's Velcade. ...

Source: You are not allowed to view links. Register or Login